News

SAN ANTONIO, Texas – Fountainhead Investment Partners is a newly formed medical investment group focused on providing funding infusions to early-staged companies that are advancing medicine through technology. To launch the fund, Fountainhead has made an initial investment in AmnioLife Corporation, a regenerative therapeutics and cellular biologics developer based in Gainesville, Fla.

Founded in 2014, Fountainhead Investment Partners has a vision to connect advancing technologies in order to solve some of medicines’ most complex issues. Fountainhead will focus its angel fund investments in areas of medical devices, surgical tools, multicellular biologics, regenerative technologies and medical knowledge management. Investments ranging from $250,000 to $1 million will be made in early-stage companies.

“Amazing research and technology is available that if it were applied to medicine would be revolutionary for the industry. Our goal is to provide financial and strategic support to companies that are accessing these resources to disrupt the science of medicine and ultimately advance patient care and quality of life,” said Brian Kieser, Fountainhead Managing Partner.

Fountainhead’s initial investment of $750,000 led AmnioLife’s Series A funding round of $833,000.  The investment will support growth around its primary manufacturing facility in Gainesville, Fla. AmnioLife will utilize the initial funding to expand and scale development of the company’s core tissue transplant technology and conduct research and development as well as preclinical studies.

“AmnioLife is producing regenerative products that restore damaged tissue and enhance and improve the healing outcomes for patients,” said Kieser. “The company’s collaborative focus on R&D, technology and human care makes AmnioLife an ideal fit for our angel fund.”

About Fountainhead Investment Partners

Fountainhead Investment Partners was founded in 2014 by a group of successful healthcare entrepreneurs that recognized how collaborating research and technology from all industries and bringing the resources to medicine could be disruptive and accelerate advancement of healthcare technology.

Fountainhead is an angel fund that supports early-stage companies with investments ranging from $250,000 to $1 million.  Partners work side-by-side with portfolio companies on operations strategies and management guidance in order to maximize the highest potential growth.

Media Contact:
Bonnie Caver
Reputation Lighthouse
512-832-8588